167 results
Page 2 of 9
8-K
EX-10.1
8qef4ctwxf7
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
6315u3dl w0
22 May 23
Business combination disclosure
7:01am
8-K
b0xgpora 1m1wb
22 May 23
Other Events
6:59am
424B3
himggr
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
EX-5.1
aiq2ii 1hclzb
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4/A
6ih8eapnf lfky5x
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
4eqmhcmk e6o7rzt
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-99.1
otoasps0k04c2ug4
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
i0nch79 jz6h
4 Aug 22
Adaptimmune Reports Second-Quarter Financial Results and Business Update
7:36am
8-K
EX-99.1
owy1ijm7gbwimcq6pfv
9 May 22
Adaptimmune Reports First Quarter Financial Results and Business Update
7:40am
8-K
ormfuuot57
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
8-K
EX-10.1
p8c9ljg7wu1nn5c0
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
424B5
hf0680rxnouzt7g
28 Apr 22
Prospectus supplement for primary offering
8:09am